H.C. Wainwright raised the firm’s price target on Greenwich LifeSciences (GLSI) to $50 from $39 and keeps a Buy rating on the shares. The firm cites the positive efficacy in the non-HLA-A*02 arm of the ongoing Phase 3 FLAMINGO-01 trial of GLSI-100 in breast cancer for the target boost. GLSI-100 reduced breast cancer recurrence by 80% in the non- HLA-A*02 arm, the analyst tells investors in a research note. H.C. Wainwright views the preliminary data as “highly encouraging,” saying it could double the market for GLSI-100.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLSI:
- Greenwich LifeSciences extends lock-up of directors, officers to September 30
- Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters
- Greenwich LifeSciences provides update on FLAMINGO-01 trial
- Greenwich LifeSciences Stockholders Reelect Board and Auditor
- Greenwich announces 80% recurrence rate reduction in FLAMINGO-01 arm